Study of Dupilumab in children with prurigo nodularis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and under 18 years old.
- They must have had prurigo nodularis (itchy, hard bumps) for at least 3 months, with at least 6 bumps on the body.
- The worst itch must be rated as 7 or higher on a 0-10 scale over the last week, unless your child is under 6 years old (then scratching counts).
- You need to be willing to fill out a daily symptom diary for the study.
- Your child cannot have other skin conditions like eczema or psoriasis that interfere, and no recent infections requiring antibiotics.
- They cannot have taken certain biologic drugs or immune-suppressing medicines recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
Hear when a new Prurigo Nodularis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.